Skip to content
Screener

Castle Biosciences CSTL Q2 2026 earnings

Reported July 30, 2026 · After market close

Revenue$103.5MBeat by $17.3M
EPS-$0.07Beat by $0.34
Revenue estimate$86.2M
EPS estimate-$0.41
“We believe our strong growth through the first half of 2026 demonstrates the clinical value our tests bring to patient care and the dedication of our talented team to deliver results so that our clinician customers and patients can act with confidence.”
Derek Maetzold

Next report

Nov 5, 2026 (In 2 days)
Revenue estimate$92.8M
EPS estimate-$0.35

Financials

Q2 2026

Income statement

See full
Revenue$103.5M+20.1%
Gross profit$79.8M+16.5%
Operating income-$3.1M+27.8%
Net income-$2.1M-146%
EPS (diluted)-$0.07-147%

Balance sheet

See full
Cash & equivalents$62.1M-24.5%
Total debt$36.7M-1.9%
Total equity$470.0M+3.2%
Total assets$561.2M+3.0%

Cash flow

See full
CapEx$8.7M-6.6%

Valuation & ratios

Valuation

as of 11/02/26
See full
Market cap$1.14B+50.6%
Enterprise value$1.11B+57.3%
P/S3.2×+1.0×

Profitability

See full
Gross margin77.3%-3.7pp
Operating margin-9%+4.8pp
Net margin-5.4%+441pp

Returns & leverage

See full
Return on equity-4.2%+77.6pp
Debt / equity0.1×0.0×
Current ratio6×-0.8×

Segments

By product

See full
Non-Dermatologic$54.8M+83.5%
Dermatologic$48.7M-13.5%

By segment

See full
Reportable Segment$103.5M+20.1%

FAQ

When did Castle Biosciences report Q2 2026 earnings?
Castle Biosciences (CSTL) reported Q2 2026 earnings on July 30, 2026 after market close.
What were Castle Biosciences's Q2 2026 revenue and EPS?
Castle Biosciences reported revenue of $103.5M and eps of $-0.07 for Q2 2026.
Did Castle Biosciences beat estimates in Q2 2026?
Revenue beat the consensus estimate of $86.2M by $17.3M. EPS beat the consensus estimate of $-0.41 by $0.34.
How did Castle Biosciences's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 20.1% from $86.2M a year earlier.
Where can I find Castle Biosciences's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-051045) and the 10-Q periodic report (0001628280-26-051052) directly on SEC EDGAR. The filing index links above go to sec.gov.